Brief: AB Science Announced Publication Of Masitinib Phase 3 Clinical Trial In Alzheimer’S Disease

AB Science SA

28/02/2023 07:08

Feb 28 (Reuters) - AB Science SA  ABS.PA :
    * ANNOUNCED THE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3
CLINICAL TRIAL IN ALZHEIMER’S DISEASE IN THE JOURNAL ALZHEIMER'S
RESEARCH & THERAPY
    * STUDY AB09004 MET ITS PRIMARY ANALYSIS ENDPOINT
    * RESULTS SHOWED THAT MASITINIB CAN GENERATE A SIGNIFICANT
TREATMENT EFFECT RELATIVE TO PLACEBO IN PRIMARY ENDPOINT OF
ADAS-COG
    * MASITINIB GENERATED A NON-SIGNIFICANT TREND TOWARDS
IMPROVED
OVERALL FUNCTION RELATIVE TO PLACEBO AS MEASURED BY ADCS-ADL
SCORE
    * SAFETY OF MASITINIB AS AN ADJUNCT TO CHOLINESTERASE
INHIBITOR
AND/OR MEMANTINE WAS ACCEPTABLE AND CONSISTENT WITH ITS KNOWN
TOLERABILITY PROFILE

Source text for Eikon:  ID:nGNE28sRjH 
Further company coverage:  ABS.PA 

 (Gdansk newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))